Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to improve preparedness for first-time anaphylaxis incidents in rural communities.

In November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicine’s Adrenaline Auto-injector Expert Working Group, with wide-ranging input from patient groups, leading allergy experts and healthcare professionals, published a report which outlined recommendations for the safe and effective use of adrenaline auto-injectors (AAIs), including quicker treatment, to help save lives. MHRA has worked alongside the Department and the wider health system to take forward these recommendations, some of which are already in place.

In June 2023, MHRA, with the support of allergy awareness advocates, launched a safety campaign to raise awareness of anaphylaxis and provide advice on the use of AAIs. MHRA produced a toolkit of resources for health and social care professionals to support the safe and effective use of AAIs. Alongside this, MHRA produced guidance, which states that prescribers should prescribe two AAIs to make sure patients always have the second dose and that those who are prescribed AAIs should carry two AAIs at all times.

The National Institute for Health and Care Excellence has also produced guidance on assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services after emergency treatment.

Most community pharmacies offer vaccinations. As part of offering this service, pharmacy contractors are expected to recognise and treat anaphylaxis. They must have immediate access to an anaphylaxis pack, including adrenaline. They are required to undertake training to administer adrenaline from an ampoule using a needle and AAIs in case of anaphylactic reactions.

Data regarding all anaphylaxis-related deaths in England and Wales are documented by the Office for National Statistics, and the British Society for Allergy and Clinical Immunology also holds a register to capture and learn fatal cases of anaphylaxis which has been operational since 1992, the UK Fatal Anaphylaxis Register (UKFAR).

Regarding the reporting of anaphylaxis in hospitals, NHS England’s National Patient Safety Team is working with the UKFAR to develop a mechanism for sharing relevant patient safety anaphylaxis incidents. The aim will be for the UKFAR to extract and share patient safety incidents reported to the national databases, the National Reporting and Learning System and Learn from Patient Safety Events, relating to severe allergic reactions.